International analysis has found that discordant results between two types of HPV test linked with worse outcomes for patients
The study shows the need for using both HPV and p16 tests to screen for patients who test positive for one but negative for the other
Patients who have head and neck cancer caused by the human papilloma virus should be double tested, after new research solves puzzle over worsening outcomes among some people.
A major international trial published in The Lancet Oncology has looked at studies from 13 head and neck cancer centres from nine countries around the world. The data of 7,895 patients has found that there is a significant number of people who have ‘discordant’ results in which the two different tests for HPV show different results.
The study found that for the one in ten of patients who have discordant HPV results, they saw significantly worsening outcomes compared to those who tested negative in both tests.
Testing for whether a cancer is HPV related is made up of two types of tests. The first, which is called HPV testing looks for the actual virus within the tumour. The second type of test looks for a protein called P16, which has been established as a commonly used biomarker for HPV. P16 is easier to use and so most people use it as the standard.
The study was funded by Cancer Research UK, the National Institute for Health and Care Research, and the Medical Research Council and brought together collaborators from across Europe, coordinated by Professor Hisham Mehanna at the University of Birmingham.
This new research has solved the conundrum puzzling the international community about why some patients respond much better to treatment than others.
Prof Hisham Mehanna, Professor of Head and Neck Surgery at the University of Birmingham and lead author of the paper said:
“Through an international collaboration we have been able to answer a question that has perplexed the head and neck cancer community for over two decades. In that time there has been an emergence of a new type of head and neck cancer this cancer called Human papillomavirus (HPV) related head and neck cancer, caused by the same virus that is often responsible for cervical cancer.
“What is remarkable is that patients with HPV head and neck cancer respond much better to current therapies than patients who are not HPV related. As a result, we are trying to look for less toxic treatments for these patients to reduce the burden of toxicity. For patients who are HPV negative, we are doing clinical trials to increase the intensity of treatment – to try to improve outcomes.
“Therefore, testing for HPV in head and neck cancer patients has become a real priority and this new research has solved the conundrum puzzling the international community about why some patients respond much better to treatment than others.”
People who smoked had head and neck cancers that acted like HPV- cancers, which are linked with worse outcomes.
Patients with discordant tests who smoke were at much higher risk of worse outcomes, as the study found that their cancer acted like HPV negative cancers. On the other hand, patients with discordant tests who did not smoke had tumours that had good outcomes, like HPV positive cancers.
Professor Hisham Mehanna said:
“This has significant implications on how we test head and neck cancer patients moving forward, especially in regions where smoking is still prevalent and HPV disease is not prevalent. For example, southern Europe and countries in the east. It also has significant implications for how we choose which studies to enrol these patients in, and in future what treatment they get.”
For media enquiries please contact Tim Mayo, Press Office, University of Birmingham, tel: +44 (0)7920 405040
The mission of the National Institute for Health and Care Research (NIHR) is to improve the health and wealth of the nation through research. We do this by:
NIHR is funded by the Department of Health and Social Care. Its work in low and middle-income countries is principally funded through UK Aid from the UK government.
Deputy Pro-Vice Chancellor (interdisciplinary research)
Staff profile of Professor Hisham Mehanna, InHANSE, Department of Cancer and Genomic Sciences, College of Medicine and Health, University of Birmingham
